INVO Fertility (NASDAQ:IVF) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of INVO Fertility (NASDAQ:IVF) to a hold rating in a research note released on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of INVO Fertility in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $20.00.

INVO Fertility Trading Down 2.9%

Shares of INVO Fertility stock opened at $1.00 on Friday. The firm has a 50-day simple moving average of $1.20 and a two-hundred day simple moving average of $2.24. The company has a market cap of $2.51 million, a P/E ratio of -0.03 and a beta of 2.32. INVO Fertility has a fifty-two week low of $0.90 and a fifty-two week high of $84.40. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.67 and a current ratio of 0.71.

INVO Fertility (NASDAQ:IVF) last posted its earnings results on Friday, August 14th. The company reported $0.35 earnings per share (EPS) for the quarter. INVO Fertility had a negative net margin of 116.29% and a negative return on equity of 85.54%. The business had revenue of $2.18 million for the quarter.

Institutional Investors Weigh In On INVO Fertility

An institutional investor recently bought a new position in INVO Fertility stock. Citadel Advisors LLC acquired a new position in shares of INVO Fertility, Inc (NASDAQ:IVF) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned 1.19% of INVO Fertility as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 12.02% of the company’s stock.

About INVO Fertility

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.